Relatório de Análise do Tamanho, Participação e Tendências do Mercado Global de Terapias Anti-inflamatórias – Visão Geral do Setor e Previsão até 2033

Tamanho do mercado de terapêuticas anti-inflamatórias

• O mercado global de terapêuticas anti-inflamatórias foi avaliado em US$ 102,59 bilhões em 2025  e deverá atingir  US$ 169,78 bilhões em 2033 , com uma taxa de crescimento anual composta (CAGR) de 6,50% durante o período de previsão.
• O crescimento do mercado é impulsionado principalmente pela crescente prevalência de doenças inflamatórias crônicas e autoimunes, como artrite reumatoide, asma, doença inflamatória intestinal e psoríase, juntamente com o envelhecimento da população, que é mais suscetível a condições inflamatórias de longo prazo. Os avanços no desenvolvimento de medicamentos, incluindo biológicos, biossimilares e terapias direcionadas com pequenas moléculas, estão acelerando ainda mais a inovação no tratamento no mercado global de terapêuticas anti-inflamatórias.
• Além disso, o aumento dos gastos com saúde e a melhoria do acesso a opções de tratamento avançadas, juntamente com a crescente demanda por terapias anti-inflamatórias mais seguras, eficazes e personalizadas, estão impulsionando a adoção em todos os sistemas de saúde. O foco crescente na redução dos efeitos colaterais associados aos AINEs e corticosteroides convencionais também está impulsionando a mudança para novas abordagens terapêuticas direcionadas e de precisão, aumentando significativamente o crescimento do setor.

Análise do Mercado de Terapias Anti-inflamatórias

• As terapias anti-inflamatórias, que abrangem uma ampla gama de tratamentos, como anti-inflamatórios não esteroides (AINEs), corticosteroides, agentes biológicos e inibidores de pequenas moléculas direcionados, desempenham um papel fundamental no controle da dor, da inflamação e de doenças autoimunes, tanto em condições agudas quanto crônicas. Essas terapias são cada vez mais essenciais nos protocolos de tratamento modernos devido à sua eficácia aprimorada e às crescentes aplicações clínicas em doenças como artrite reumatoide, asma, doença inflamatória intestinal e psoríase.
• O crescimento do mercado é impulsionado principalmente pelo aumento da carga global de doenças inflamatórias crônicas e autoimunes, aliado ao envelhecimento da população e à crescente conscientização sobre o diagnóstico precoce e o manejo a longo prazo dessas doenças. Além disso, os avanços contínuos em medicamentos biológicos, biossimilares e abordagens de medicina de precisão estão melhorando significativamente os resultados dos tratamentos, enquanto a demanda por terapias mais seguras e com menos efeitos colaterais em comparação aos corticosteroides e anti-inflamatórios não esteroides (AINEs) convencionais está acelerando ainda mais a expansão do mercado.
• A América do Norte dominou o mercado de terapêuticas anti-inflamatórias com a maior participação na receita em 2025, impulsionada por uma infraestrutura de saúde bem estabelecida, alta adoção de terapias biológicas avançadas, forte presença de importantes empresas farmacêuticas e regimes de reembolso favoráveis. A região continua a testemunhar uma forte adoção de medicamentos anti-inflamatórios inovadores, particularmente nos EUA, impulsionada por investimentos contínuos em P&D e rápida adoção clínica de terapias-alvo de próxima geração.
• A região Ásia-Pacífico deverá ser a de crescimento mais rápido no mercado de terapêuticas anti-inflamatórias durante o período de previsão, impulsionada pela crescente urbanização, aumento dos gastos com saúde, melhoria do acesso a tratamentos avançados e um número crescente de pacientes com doenças inflamatórias crônicas. A expansão da capacidade de produção farmacêutica e o aumento da atividade de ensaios clínicos em países como China e Índia também contribuem para o crescimento do mercado regional.
• O segmento de AINEs dominou o mercado com a maior participação na receita, de 41,6% em 2025, impulsionado pelo uso generalizado no controle da dor, redução da febre e controle da inflamação em diversas condições crônicas e agudas.

Escopo do relatório e segmentação do mercado de terapêuticas anti-inflamatórias         

Anti-Inflammatory Therapeutics Market Trends

“Rising Adoption of Targeted, Biologic, and Precision-Based Anti-Inflammatory Therapies”

• A major and rapidly accelerating trend in the global anti-inflammatory therapeutics market is the shift from conventional broad-spectrum anti-inflammatory drugs toward highly targeted therapies, including biologics, biosimilars, and small-molecule inhibitors. This transition is fundamentally transforming treatment approaches by focusing on specific inflammatory pathways rather than generalized immune suppression
• Biologic drugs such as monoclonal antibodies targeting TNF-α, IL-4, IL-5, IL-6, and IL-17 are increasingly being adopted for the treatment of complex chronic conditions like rheumatoid arthritis, psoriasis, ankylosing spondylitis, and inflammatory bowel disease. These therapies offer improved clinical outcomes, longer remission periods, and reduced disease progression compared to traditional therapies
• For instance, adalimumab (Humira) and secukinumab (Cosentyx) are widely used in clinical practice for rheumatoid arthritis and psoriasis management, demonstrating strong efficacy in reducing inflammatory flare-ups
• In addition, the growing use of JAK inhibitors (Janus kinase inhibitors) represents a significant advancement, enabling oral administration with targeted intracellular signaling modulation. This has improved patient compliance while maintaining high efficacy in managing autoimmune and inflammatory conditions
• Precision medicine is also emerging as a key trend, where treatment decisions are guided by genetic markers, cytokine profiling, and disease endotypes. This enables clinicians to tailor therapies based on individual inflammatory mechanisms, thereby improving response rates and minimizing adverse effects
• The increasing integration of companion diagnostics with anti-inflammatory drugs is further strengthening this trend, allowing better patient stratification and optimized treatment selection
• Pharmaceutical companies are heavily investing in next-generation biologics with improved safety profiles, longer half-lives, and reduced immunogenicity, which is expanding treatment options for chronic inflammatory diseases
• Moreover, the development and commercialization of biosimilars are improving affordability and expanding access to biologic therapies in emerging economies, thereby accelerating market penetration
• Overall, the market is witnessing a clear shift toward mechanism-based, personalized, and long-acting therapies, which is reshaping the global treatment landscape for inflammatory disorders

Anti-Inflammatory Therapeutics Market Dynamics

Driver

“Rising Global Burden of Chronic Inflammatory and Autoimmune Diseases”

• The increasing prevalence of chronic inflammatory and autoimmune diseases is one of the strongest drivers of the Anti-Inflammatory Therapeutics market. Conditions such as rheumatoid arthritis, asthma, psoriasis, Crohn’s disease, ulcerative colitis, lupus, and multiple sclerosis are rising steadily across both developed and developing regions.

• Aging populations are particularly vulnerable to chronic inflammation due to immune system dysregulation, leading to higher incidence rates of inflammatory disorders and increasing long-term treatment demand
• For instance, elderly populations in countries like Japan and Germany show significantly higher rates of rheumatoid arthritis and osteoarthritis, driving sustained demand for anti-inflammatory therapies
• Lifestyle factors such as poor dietary habits, sedentary behavior, obesity, smoking, and rising environmental pollution are contributing significantly to the global increase in inflammatory diseases
• Improved diagnostic capabilities and increased awareness among patients and healthcare providers are leading to earlier detection and longer treatment duration, thereby expanding the overall treated patient pool
• The growing availability of advanced diagnostic tools, including biomarker-based testing and imaging technologies, is enabling more accurate disease classification and treatment planning
• Pharmaceutical innovation, including continuous pipeline expansion of biologics, JAK inhibitors, and interleukin inhibitors, is enhancing therapeutic outcomes and encouraging greater adoption of prescription anti-inflammatory drugs
• Increasing healthcare expenditure across emerging economies such as India, China, and Brazil is improving access to specialty care and advanced therapies, significantly contributing to market growth
• Expansion of healthcare infrastructure, including specialty clinics and infusion centers, is also facilitating wider adoption of advanced anti-inflammatory treatments
• In addition, rising patient preference for long-term disease control rather than symptomatic relief is driving demand for disease-modifying anti-inflammatory therapies instead of conventional pain-relief medications
• The growing role of pharmaceutical collaborations, clinical trials, and regulatory approvals for novel therapies is further accelerating market expansion globally

Restraint/Challenge

“High Cost of Advanced Therapies and Safety Concerns Associated with Long-Term Immunomodulation”

• A key challenge limiting the growth of the Anti-Inflammatory Therapeutics market is the high cost associated with advanced biologics, monoclonal antibodies, and targeted small-molecule therapies. These treatments often require long-term or lifelong administration, resulting in significant financial burden for patients and healthcare systems
• In many regions, limited reimbursement coverage and uneven insurance penetration further restrict patient access to high-cost therapies, particularly in low- and middle-income countries
• For instance, biologic treatments for rheumatoid arthritis remain unaffordable for a large proportion of patients in developing markets such as parts of South Asia and Africa due to limited insurance support
• Although biosimilars are gradually improving affordability, adoption remains uneven due to physician hesitation, regulatory variability, and concerns regarding interchangeability and efficacy equivalence
• Another major restraint is the safety risk associated with long-term immunosuppression. Many anti-inflammatory therapies, especially biologics and JAK inhibitors, can increase susceptibility to infections such as tuberculosis, pneumonia, and opportunistic infections
• There is also a documented risk of potential long-term adverse outcomes, including malignancies, cardiovascular complications, and liver toxicity in certain patient populations, which raises concerns among prescribers and patients
• Corticosteroids, though widely used and cost-effective, are associated with severe long-term side effects such as osteoporosis, weight gain, diabetes, hypertension, and adrenal suppression, limiting their prolonged use
• Treatment adherence is also affected due to chronic therapy requirements, injection-based administration for some biologics, and frequent monitoring needs, which can reduce patient compliance over time
• High research and development costs, coupled with stringent regulatory approval pathways for biologics and novel immunotherapies, further increase market entry barriers for new players
• In addition, pricing pressures from healthcare payers and government cost-containment policies are forcing pharmaceutical companies to balance innovation with affordability, slowing down market expansion in certain regions

Anti-Inflammatory Therapeutics Market Scope

The market is segmented on the basis of drug class, indications, end-users, and distribution channel.

• By Drug Class

On the basis of drug class, the Anti-Inflammatory Therapeutics market is segmented into Anti-Inflammatory Biologics, Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and Others. The NSAIDs segment dominated the market with the largest revenue share of 41.6% in 2025, driven by widespread use in pain management, fever reduction, and inflammation control across multiple chronic and acute conditions. NSAIDs are highly preferred due to their over-the-counter availability, cost-effectiveness, and rapid symptom relief. Their extensive use in arthritis, musculoskeletal disorders, and post-surgical inflammation further strengthens demand. Physicians frequently prescribe NSAIDs as first-line therapy due to their well-established efficacy and safety profile. Increasing prevalence of lifestyle-related inflammatory conditions supports market expansion. Strong penetration in both developed and emerging economies enhances accessibility. Continuous innovation in selective COX-2 inhibitors improves gastrointestinal safety and patient compliance. High prescription volume in hospitals and clinics reinforces dominance. Overall, NSAIDs remain the backbone of anti-inflammatory therapy globally.

The Anti-Inflammatory Biologics segment is expected to witness the fastest CAGR of 14.8% from 2026 to 2033, driven by rising adoption of targeted therapies for chronic autoimmune and inflammatory diseases. Biologics offer high specificity by targeting immune pathways, improving treatment outcomes in conditions like rheumatoid arthritis and psoriasis. Increasing clinical preference for precision medicine supports growth. Strong pipeline of monoclonal antibodies and biosimilars enhances accessibility. Higher efficacy in patients unresponsive to conventional drugs accelerates adoption. Expanding approvals for new indications further boost demand. Rising healthcare expenditure and insurance coverage improvements support affordability. Biologics also reduce long-term disease progression and hospitalizations. Pharmaceutical innovation and R&D investments are rapidly expanding this segment. Overall, Anti-Inflammatory Biologics represent the fastest-growing drug class segment.

• By Indications

Com base nas indicações, o mercado de terapêuticas anti-inflamatórias é segmentado em artrite, doenças respiratórias, esclerose múltipla, psoríase, doença inflamatória intestinal e outras. O segmento de artrite dominou o mercado com uma participação de 38,9% da receita em 2025, impulsionado pela alta prevalência global de osteoartrite e artrite reumatoide, particularmente entre a população idosa. O aumento dos casos de degeneração articular e distúrbios musculoesqueléticos relacionados ao estilo de vida contribuem significativamente para a demanda. Anti-inflamatórios não esteroides (AINEs), corticosteroides e biológicos são amplamente utilizados para o controle dos sintomas e da doença. O crescimento da população idosa em todo o mundo acelera ainda mais o crescimento do mercado. Taxas de diagnóstico aprimoradas permitem a detecção precoce e o início do tratamento. Fortes padrões de prescrição em hospitais e clínicas especializadas sustentam a dominância do mercado. O desenvolvimento contínuo de terapias biológicas avançadas melhora os resultados do tratamento. A conscientização dos pacientes sobre as opções de controle da dor também impulsiona a adoção desses medicamentos. Iniciativas governamentais na área da saúde melhoram o acesso a terapias anti-inflamatórias. No geral, a artrite continua sendo o maior segmento de indicação no mercado.

O segmento de Doença Inflamatória Intestinal (DII) deverá apresentar a taxa de crescimento anual composta (CAGR) mais rápida, de 15,2%, entre 2026 e 2033, impulsionado pelo aumento da incidência da doença de Crohn e da colite ulcerativa em todo o mundo. A crescente conscientização e a melhoria das capacidades de diagnóstico contribuem para a identificação precoce da doença. As terapias biológicas que têm como alvo as vias imunológicas são cada vez mais preferidas para casos moderados a graves. Mudanças no estilo de vida, padrões alimentares e predisposição genética contribuem para o aumento da prevalência. Uma sólida linha de anticorpos monoclonais avançados e biossimilares apoia a rápida adoção. A crescente demanda por soluções de gerenciamento da doença a longo prazo impulsiona o uso terapêutico. A adoção por hospitais e centros especializados está aumentando devido aos complexos requisitos de tratamento. A expansão do acesso à saúde em economias emergentes acelera ainda mais o crescimento. A preferência dos pacientes por terapias direcionadas e eficazes aumenta a penetração no mercado. No geral, a DII é o segmento de indicação com o crescimento mais rápido.

• Por usuários finais

Com base nos usuários finais, o mercado de terapêuticas anti-inflamatórias é segmentado em hospitais, assistência domiciliar, centros especializados e outros. O segmento de hospitais dominou o mercado com uma participação de 52,4% da receita em 2025, impulsionado pelo alto fluxo de pacientes com condições inflamatórias agudas e crônicas que requerem tratamento supervisionado. Os hospitais servem como centros primários para diagnóstico, prescrição e administração de terapias anti-inflamatórias avançadas, incluindo biológicos e corticosteroides. A disponibilidade de profissionais de saúde qualificados garante o manejo eficaz da doença. A forte adoção de terapias de infusão hospitalares para biológicos sustenta essa dominância. A integração de ferramentas de diagnóstico avançadas melhora a precisão do tratamento. Os sistemas de financiamento e reembolso governamentais aumentam a acessibilidade. Os hospitais também atuam como centros-chave para ensaios clínicos e adoção de medicamentos inovadores. Os altos volumes de pacientes internados e ambulatoriais fortalecem ainda mais a participação de mercado. Os modelos de atendimento multidisciplinar melhoram os resultados para os pacientes. No geral, os hospitais permanecem o principal segmento de usuários finais globalmente.

O segmento de cuidados domiciliares deverá apresentar a taxa de crescimento anual composta (CAGR) mais rápida, de 16,4%, entre 2026 e 2033, impulsionado pela crescente preferência por abordagens de tratamento convenientes e centradas no paciente. A crescente adoção de medicamentos biológicos autoadministrados e anti-inflamatórios orais também contribui para esse crescimento. Os avanços tecnológicos em dispositivos de administração de medicamentos permitem a administração segura em casa. O aumento da população idosa e a carga de doenças crônicas impulsionam a demanda por cuidados domiciliares. A relação custo-benefício, comparada às visitas hospitalares, incentiva a adoção. A telemedicina e o monitoramento remoto de pacientes aprimoram ainda mais a adesão ao tratamento. Os pacientes preferem cada vez mais conforto e flexibilidade em terapias de longo prazo. Os sistemas de saúde estão promovendo ativamente os cuidados domiciliares para reduzir a sobrecarga hospitalar. A expansão da cobertura de planos de saúde facilita o acesso. No geral, os cuidados domiciliares representam o segmento de usuários finais com o crescimento mais rápido.

• Por canal de distribuição

Com base no canal de distribuição, o mercado de medicamentos anti-inflamatórios é segmentado em farmácias hospitalares, farmácias online e farmácias de varejo. O segmento de farmácias hospitalares dominou o mercado com uma participação de 46,7% da receita em 2025, impulsionado pelo alto volume de prescrições para condições inflamatórias agudas e protocolos de tratamento hospitalares. As farmácias hospitalares garantem a disponibilidade imediata de medicamentos anti-inflamatórios essenciais, incluindo biológicos e corticosteroides. A integração com os serviços de internação e ambulatoriais facilita a dispensação eficiente de medicamentos. Sistemas robustos de compras e acordos de compra em grande escala aumentam a disponibilidade e a relação custo-benefício. Os médicos preferem as farmácias hospitalares para a dispensação controlada e monitorada. A infraestrutura de saúde pública fortalece ainda mais essa posição dominante. As farmácias hospitalares também gerenciam os requisitos de armazenamento especializado para biológicos. A alta rotatividade de pacientes nos hospitais garante uma demanda constante. A supervisão clínica assegura a adesão às diretrizes de tratamento. No geral, as farmácias hospitalares continuam sendo o principal canal de distribuição.

O segmento de farmácias online deverá apresentar a taxa de crescimento anual composta (CAGR) mais rápida, de 17,1%, entre 2026 e 2033, impulsionado pela crescente digitalização da saúde e pela preferência cada vez maior dos consumidores por acesso facilitado a medicamentos. A expansão da penetração da internet e o uso de smartphones contribuem para a rápida adoção desse segmento. As plataformas online oferecem entrega em domicílio, modelos de assinatura e preços com desconto. A crescente aceitação das regulamentações para farmácias online aumenta a credibilidade do setor. Pacientes com doenças inflamatórias crônicas preferem compras online recorrentes pela conveniência. A integração com plataformas de telemedicina fortalece ainda mais a demanda. Os sistemas de pagamento digital facilitam as transações. A expansão da infraestrutura logística permite a entrega pontual, mesmo em áreas remotas. A crescente conscientização sobre os serviços de saúde digital acelera a penetração no mercado. Em suma, as farmácias online representam o canal de distribuição de crescimento mais rápido.

Análise Regional do Mercado de Terapias Anti-inflamatórias

• A América do Norte dominou o mercado de terapêuticas anti-inflamatórias com a maior participação na receita em 2025, impulsionada por uma infraestrutura de saúde bem estabelecida, alta adoção de terapias biológicas avançadas, forte presença de importantes empresas farmacêuticas e estruturas de reembolso favoráveis.
• A região se beneficia do uso disseminado de medicamentos biológicos, anticorpos monoclonais e terapias direcionadas para doenças como artrite reumatoide, psoríase e doença inflamatória intestinal. Por exemplo, a alta adoção de inibidores de TNF e inibidores de interleucina nos EUA e no Canadá contribuiu significativamente para melhores resultados no tratamento dessas doenças.
• This dominance is further reinforced by continuous R&D investments, early access to innovative drugs, strong regulatory support, and increasing awareness regarding chronic inflammatory diseases, establishing advanced anti-inflammatory therapeutics as a standard of care across both hospital and outpatient settings

U.S. Anti-Inflammatory Therapeutics Market Insight

The U.S. anti-inflammatory therapeutics market captured the largest revenue share in 2025 within North America, fueled by strong adoption of advanced biologics and targeted therapies. The country’s robust pharmaceutical ecosystem, presence of leading market players, and high healthcare spending significantly contribute to market growth. Consumers and healthcare providers are increasingly prioritizing early diagnosis and long-term disease management, leading to higher prescription rates of immunomodulators and biologics. In addition, favorable reimbursement policies and rapid approval of novel therapies further accelerate market expansion. Moreover, continuous innovation in drug development, including JAK inhibitors and biosimilars, along with increasing clinical trials, is significantly contributing to the growth of the Anti-Inflammatory Therapeutics market in the U.S.

Europe Anti-Inflammatory Therapeutics Market Insight

The Europe Anti-Inflammatory Therapeutics market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing prevalence of chronic inflammatory diseases and strong government support for healthcare systems. The region is witnessing growing adoption of biosimilars as cost-effective alternatives to biologics. For instance, countries such as Germany and France have implemented policies encouraging biosimilar uptake, improving patient access to advanced therapies. In addition, rising aging population, increasing healthcare awareness, and expanding access to specialty treatments are supporting market growth across both Western and Eastern Europe.

U.K. Anti-Inflammatory Therapeutics Market Insight

The U.K. anti-inflammatory therapeutics market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing burden of autoimmune diseases and rising demand for effective long-term treatment solutions. The presence of structured healthcare systems and reimbursement support for biologics and specialty drugs is encouraging adoption. Furthermore, initiatives by public health bodies to improve early diagnosis and treatment accessibility are contributing to market expansion. The country is also witnessing increased use of biosimilars and cost-effective treatment alternatives, supporting sustainable healthcare delivery while maintaining treatment quality.

Germany Anti-Inflammatory Therapeutics Market Insight

The Germany anti-inflammatory therapeutics market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced healthcare infrastructure and strong emphasis on pharmaceutical innovation. Germany is one of the leading adopters of biologics and biosimilars in Europe. For instance, widespread use of biosimilar TNF inhibitors has improved treatment accessibility for patients with chronic inflammatory diseases. In addition, increasing investments in research, strong regulatory frameworks, and growing focus on precision medicine are driving the adoption of advanced anti-inflammatory therapies in the country.

Asia-Pacific Anti-Inflammatory Therapeutics Market Insight

The Asia-Pacific anti-inflammatory therapeutics market is expected to be the fastest-growing region during the forecast period, driven by increasing urbanization, rising healthcare expenditure, improving access to advanced treatments, and a rapidly growing patient population suffering from chronic inflammatory conditions. The region is witnessing expanding pharmaceutical manufacturing capabilities and increasing clinical trial activity. For instance, countries such as China and India are emerging as key hubs for biologics production and clinical research, enhancing the availability of cost-effective therapies. Furthermore, improving healthcare infrastructure, government initiatives supporting healthcare access, and growing awareness regarding autoimmune diseases are significantly contributing to market growth across the region.

Japan Anti-Inflammatory Therapeutics Market Insight

The Japan Anti-Inflammatory Therapeutics market is gaining momentum due to its advanced healthcare system, aging population, and increasing prevalence of chronic inflammatory diseases. The country has a strong focus on innovative drug development and rapid adoption of advanced biologics. For instance, Japan has seen increased use of targeted therapies for rheumatoid arthritis and inflammatory bowel diseases, supported by favorable regulatory pathways. In addition, rising healthcare spending and emphasis on improving patient outcomes are driving demand for next-generation anti-inflammatory treatments.

China Anti-Inflammatory Therapeutics Market Insight

The China anti-inflammatory therapeutics market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to rapid urbanization, expanding middle-class population, and increasing healthcare investments. The country is witnessing strong growth in domestic pharmaceutical manufacturing and biosimilar development. For instance, local companies are actively producing cost-effective biologics, improving accessibility to advanced anti-inflammatory treatments.

Government initiatives promoting healthcare reforms, expansion of insurance coverage, and increasing clinical research activities are further propelling the Anti-Inflammatory Therapeutics market in China.

Anti-Inflammatory Therapeutics Market Share

The Anti-Inflammatory Therapeutics industry is primarily led by well-established companies, including:

• Pfizer (U.S.)
• AbbVie (U.S.)
• Roche (Switzerland)
• Johnson & Johnson (U.S.)
• Novartis (Switzerland)
• Sanofi (France)
• Bristol Myers Squibb (U.S.)
• Amgen (U.S.)
• Merck & Co. (U.S.)
• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K.)
• GlaxoSmithKline (U.K.)
• Teva Pharmaceutical Industries (Israel)
• Bayer (Germany)
• Boehringer Ingelheim (Germany)
• UCB Pharma (Belgium)
• Takeda Pharmaceutical Company (Japan)
• Sun Pharmaceutical Industries (India)
• Lupin (India)
• Dr. Reddy’s Laboratories (India)

Latest Developments in Global Anti-Inflammatory Therapeutics Market

• In July 2024, community-reported industry news highlighted early-stage progress by Ensho Therapeutics with oral anti-inflammatory candidate NSHO-101, aimed at improving therapeutic options for inflammatory bowel disease, illustrating ongoing innovation in small-molecule approaches
• In July 2025, Novartis entered a major collaboration agreement with U.S. biotech Matchpoint Therapeutics, committing up to $1 billion to develop new oral anti-inflammatory therapies that target pro-inflammatory signaling pathways, with Matchpoint leading research and Novartis holding an option for global rights to develop and commercialize resulting treatments
• In October 2025, the U.S. Food and Drug Administration (FDA) expanded the approved use of Tezspire (tezepelumab-ekko) — a biologic developed by Amgen and AstraZeneca — to include treatment for chronic rhinosinusitis with nasal polyps, a chronic inflammatory condition, reflecting broader regulatory recognition of anti-inflammatory biologics beyond their original indications
• In December 2025, Kymera Therapeutics reported promising Phase 1b clinical trial results for its oral anti-inflammatory drug candidate KT-621, which targets STAT6 — a key transcription factor in Type 2 inflammatory diseases such as atopic dermatitis and asthma — leading to strong investor interest and a notable stock surge
• In May 2025, according to industry community reports, Abivax completed enrollment of approximately 1,275 participants in its Phase 3 ABTECT trial for a novel therapy targeting ulcerative colitis, an inflammatory bowel disease, marking a significant clinical development milestone in anti-inflammatory therapeutic research
• In May 2025, the European Commission approved TREMFYA (guselkumab) for adults with moderately to severely active ulcerative colitis, expanding the use of this anti-inflammatory biologic and enhancing treatment options for patients with chronic inflammatory bowel disease in Europe.

SKU-54005